Lower Costs in Breast Cancer: How This Affects Treatment

Lower Costs in Breast Cancer: How This Affects Treatment

3 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Courtney Williams, MPH @cphilwil of @ONealCancerUAB explains findings in a new study that results in lower costs and how this affects treatment and clinicians today.

__________

Research from the UAB's O'Neal Comprehensive Cancer Center finds that patients treated outside the recommendations of the NCCN Guidelines had significantly greater direct costs.

A new study by the O'Neal Comprehensive Cancer Center at the University of Alabama in Birmingham (UAB), published in the October 2019 issue of JNCCN— Journal of the National Comprehensive Cancer Network, finds that direct costs for patients with metastatic breast cancer (MBC) increase dramatically when their treatment differs from the NCCN Clinical Practice Guidelines for Oncology (NCCN) recommendations. Previous studies have found that disagreeable care leads to higher overall health care costs[1], but this is the first study to look specifically at the cost burden for patients.

“We thought that it was important to explore potential differences in out-of-pocket costs, since financial toxicity is a growing issue among patients with metastatic breast cancer,” explained Courtney P. Williams, MPH, Division of Hematology and Oncology, O’Neal Comprehensive Cancer Center at UAB. “We found about one in five women received an anticancer treatment that wasn’t listed within the NCCN Guidelines. Those women were responsible for higher out-of-pocket costs—including deductibles, coinsurance, and copayments—in the year following their metastatic breast cancer diagnosis than those receiving an anticancer treatment listed within the guidelines. This finding is especially important for older patients, which made up about 75 percent of our sample, since financial and psychological distress could be worse for patients living on a fixed income.”

The retrospective study used the SEER-Medicare registry to look at the cost of patients of 3,709 women diagnosed with MBC from 2007 to 2013 who survived at least one year after diagnosis. Diagnosis plans have been linked to the version of the Breast Cancer NCCN Guidelines ® available at the exact date of diagnosis. Due to NCCN's regular guideline revisions, the concept of guideline-concordant treatment varied depending on the date.

The average post-diagnosis patient cost for the year was $5,171 for treatment that fit the current NCCN recommendations, compared to $7,421 for care that deviated from them. Overtreatment and undertreatment, as described in the guidelines, eventually resulted in higher costs for patients.

Read here: https://www.oncologytube.com/video/nccn-recommendations-for-metastatic-breast-cancer-lowers-costs-for-patients-according-to-the-new-study-

Up Next Autoplay
An Advocates Perspective to Increasing Funding Resources
An Advocates Perspective to Increasing Funding Resources
Category: Kidney Cancer
26 Views
kidneycancer 22 hours
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
7 Views
UVA Cancer Center 23 hours
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
3 Views
Cancer-News 1 day
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
11 Views
kidneycancer 1 day
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
8 Views
kidneycancer 1 day
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
4 Views
CURC 2 days
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 2 days
ProVent Trial Changing AS Landscape @UrologyUS
ProVent Trial Changing AS Landscape @UrologyUS
Category: Prostate Cancer
3 Views
CURC 2 days
Current Treatment Options in the ProVent Trial
Current Treatment Options in the ProVent Trial
Category: Prostate Cancer
3 Views
CURC 2 days
Phase 3 ProVent Clinical Trial @UrologyUS
Phase 3 ProVent Clinical Trial @UrologyUS
Category: Prostate Cancer
4 Views
CURC 2 days